In a nutshell This study evaluated lenalidomide (Revlimid) maintenance therapy versus placebo for patients with diffuse large B-cell lymphoma (DLBCL). The authors found that lenalidomide increased the number of side effects but did not impact health status. Some background DLBCL is an aggressive type of non-Hodgkin's lymphoma....
Read MoreCurrent disease status-First occurrence of the lymphoma Posts on Medivizor
Evaluating subcutaneous rituximab for patients with non-Hodgkin lymphoma
In a nutshell This study examined whether it is safe to switch from intravenous to subcutaneous rituximab (Rituxan) during first-line treatment of non-Hodgkin's lymphoma (NHL). The authors concluded that subcutaneous rituximab was safe and effective, and improved quality of life for patients. Some background Rituximab is a standard...
Read MoreWhat factors can predict the success of stem cell transplantation for patients with lymphoma?
In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...
Read MoreEvaluating brentuximab vedotin for patients with relapsed or unresponsive Hodgkin lymphoma after SCT
In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...
Read MoreLymphoma transformation risk in patients with advanced follicular lymphoma
In a nutshell This study investigated the frequency of lymphoma transformation in patients with advanced-stage follicular lymphoma (FL) after treatment with BR (bendamustine, rituximab). This study concluded these patients might be at risk for lymphoma transformation after initial treatment. Some background FL is the second most common type of...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreFertility options for female patients with lymphoma or leukemia
In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...
Read MoreCan immune profiling help predict outcomes for patients with NHL after a stem cell transplant?
In a nutshell This study compared the outcomes of filgrastim (Neupogen) treatment with versus without plerixafor (Mozobil) in patients with B-cell non-Hodgkin's lymphoma (NHL) after a stem cell transplant. The authors concluded that certain immune cell biomarkers were associated with poorer long-term survival for these patients. Some...
Read MoreEvaluating different doxorubicin doses for patients with diffuse large B-cell lymphoma
In a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...
Read MoreLooking for patients with previously untreated mantle cell lymphoma to test a treatment combination
In a nutshell This phase 3 study is evaluating the effectiveness and safety of two different chemotherapy regimens for patients with mantle cell lymphoma (MCL). The main outcome to be measured will be the number of patients who survive without tumor growth or spread. This study is recruiting in Las Vegas, Nevada in the U.S. The details MCL is an...
Read MoreFirst-line treatment options for patients with Hodgkin’s lymphoma
In a nutshell This article reviewed different options for first-line treatment for Hodgkin lymphoma (HL). Some background Treatment for patients with HL has become more individualized. Treatment strategies have been adapted to disease risk, and how well patients respond to initial treatment. The goal of these approaches is to reduce side effects...
Read MoreSearching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...
Read More
